Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

IRLAB’s Phase IIb pirepemat data highlights opportunity in Parkinson’s disease falls management, says GlobalData

Integrative Research Laboratories Sweden AB’s (IRLAB) Phase IIb REACT-PD trial results for pirepemat highlight both the promise and the complexity of targeting non-dopaminergic symptoms in Parkinson’s disease (PD), particularly falls and balance impairment, which remain major unmet needs, says GlobalData, a leading intelligence and productivity platform. Presented at the AD/PD 2026 International Conference, the REACT-PD […]
Read more

Ecnoglutide approval intensifies competition in China GLP-1 obesity market, says GlobalData

China’s approval of Sciwind Biosciences’ Ecnoglutide injection as the fifth GLP-1 obesity therapy signals intensifying competition in one of the world’s fastest-growing metabolic drug markets. Strong Phase III efficacy and a landmark commercialization partnership with Pfizer highlight rising strategic interest in obesity treatments, positioning China as a key battleground for innovation, pricing competition, and global […]
Read more

Proposed US childhood vaccine cuts threaten domestic manufacturing demand, says GlobalData

Proposed cuts to the US childhood immunization schedule and weakening state-level vaccine mandates threaten to erode domestic vaccine demand, placing pressure on the country’s manufacturing base. As the industry already adjusts to the post-COVID-19 normalization of vaccine demand, declining vaccination rates and policy shifts risk undermining production volumes, sales prospects, and long-term investment incentives for […]
Read more

TrumpRx and Medicare highlight shifting pharma industry priorities, says GlobalData

The US administration’s TrumpRx initiative and a proposed Medicare incentive rule link drug pricing, tariff policy, and domestic manufacturing in a coordinated push to reshore pharmaceutical production, highlighting shifting industry priorities, says GlobalData, a leading intelligence and productivity platform. Launched in February 2026, TrumpRx enables cash-paying and uninsured patients to access selected branded medicines at […]
Read more

Model Medicines’ MDL-001 holds potential to strengthen pandemic preparedness across multiple infectious diseases, says GlobalData

Model Medicines presented an update on its lead candidate MDL-001 at the Biocom Global Partnering Conference in California, positioning the asset as a first-in-class oral direct-acting antiviral with demonstrated preclinical activity across various viral families, including respiratory, hepatic, and gastrointestinal viruses. With such a broad therapeutic spectrum, MDL-001 has potential to address unmet needs including […]
Read more

Shifting operating landscape for pharma and biotech: Join GlobalData’s webinar for 2026 outlook

Mounting geopolitical tensions, evolving trade policies, regulatory reform, and structural changes in global health financing are reshaping the operating environment for pharmaceutical and biotech companies. Against this complex backdrop, growth expectations for healthcare spending and pharmaceutical sales are being recalibrated across major markets, says GlobalData, a leading intelligence and productivity platform. To assess these developments, […]
Read more

 argenX’s Vyvgart holds potential to break into ocular myasthenia gravis market, says GlobalData

argenX recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered by prefilled syringe in adult patients with ocular MG (MGFA Class I) who are acetylcholine receptor antibody–positive (AChR+). The results demonstrate Vyvgart’s potential for early […]
Read more

Merck’s DOR/ISL will compete with standard of care as a 2-drug STR, says GlobalData

A Phase III switch study occurring over 96 weeks has demonstrated that Merck’s doravirine/islatravir (DOR/ISL) sustains durable viral suppression with stable safety outcomes in virologically suppressed adults with HIV, reinforcing momentum behind two-drug single-tablet regimens (STR). The data positions DOR/ISL as a credible integrase-sparing challenger in a market recalibrating toward simplified, lower-toxicity maintenance strategies ahead […]
Read more

Unmet needs remain substantial in progressive pulmonary fibrosis, says GlobalData

Progressive pulmonary fibrosis (PPF) represents one of the most challenging phenotypes within the interstitial lung disease (ILD) space and is defined by worsening fibrosis observed by high-resolution computed tomography scans, declining lung function, and persistent symptoms. Although the approval of antifibrotics have expanded treatment options in recent years, they primarily slow functional decline rather than […]
Read more

Knight’s axatilimab regulatory submission in Brazil indicates growth in GvHD therapeutics, says GlobalData

Knight Therapeutics’ regulatory submission of Niktimvo (axatilimab) in Brazil marks an important milestone in expanding access to novel therapies for chronic graft-versus-host disease (cGvHD) across Latin America. The filing reflects growing regional momentum in advanced immunology and transplant-related therapies, highlighting Brazil’s strategic importance as a key pharmaceutical market in the region, says GlobalData, a leading […]
Read more

AbbVie’s $100 billion US deal and FDA reforms highlight growing focus on domestic manufacturing, says GlobalData

AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to domestic manufacturing expansion. Coupled with the evolving US Food and Drug Administration manufacturing reforms, the deal underscores a policy-driven shift that embeds capital investment, supply chain resilience, and advanced biologics capacity […]
Read more

Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData

Huahui Health has recently secured conditional approval from China’s National Medical Products Administration (NMPA) for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. This move not only addresses a critical treatment gap but also signals China’s […]
Read more

FDA reversal on Moderna’s mRNA-1010 can transform the seasonal influenza vaccines market, says GlobalData

The US Food and Drug Administration’s (FDA) decision to review Moderna’s mRNA-1010, with a Prescription Drug User Fee Act (PDUFA) date set for 05 August 2026, signals a pivotal inflection point for the seasonal influenza vaccines market. If approved, the candidate will introduce the first mRNA-based flu vaccine, potentially redefining production timelines, strain matching precision, […]
Read more

Systemic lupus erythematosus and lupus nephritis market to reach $5.9 billion in 7MM by 2034, forecasts GlobalData

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM*) is forecast to grow from $2.4 billion in 2024 to $5.9 billion in 2034, at a compound annual growth rate (CAGR) of 9.6%, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Systemic Lupus Erythematosus and […]
Read more

Global pain market presents significant opportunities for novel mechanisms and modalities, says GlobalData

There is a lack of diversity within the current pain market, with non-steroidal anti-inflammatory drugs (NSAIDs) and opioids dominating the market. With 98% of currently marketed drugs for pain being generics, the pain market provides significant opportunities for innovation and development, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Global Pain […]
Read more

Pricing and reimbursement delays critical headwind for biopharmaceutical industry innovation, finds GlobalData

Delays in turning approved medicines into revenue, driven by pricing and reimbursement (P&R) processes, have emerged as one of the most critical challenges facing the pharmaceutical industry over the next year. Industry professionals now rank pricing pressure alongside innovation-led trends, underscoring growing concerns that tougher price controls and policy shifts could erode revenues, slow launches, […]
Read more

Insmed’s treprotinil palmitil phase III study signals potential shift in progressive pulmonary fibrosis treatment, says GlobalData

At the 44th annual J.P. Morgan Healthcare conference, Insmed delivered one of the most closely watched updates in the respiratory space, detailing its clinical and commercial plans for 2026. Among the highlights was the company’s announcement to launch a Phase III study for its treprostinil palmitil inhalation powder (TPIP) in progressive pulmonary fibrosis (PPF) during […]
Read more

Eliquis sales to fall by 15.2% in 2026 as European patent expiry nears, forecasts GlobalData

Global sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% in 2026 due to the loss of its European market exclusivity on May 19, 2026, according to GlobalData, a leading intelligence and productivity platform. According to GlobalData’s Pharmaceutical Intelligence Center Sales and Forecast Database, the BMS-Pfizer alliance […]
Read more
1 … 3 4 5 6 7 … 110